Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Among authors: bremnes rm. Br J Cancer. 2007 Aug 6;97(3):283-9. doi: 10.1038/sj.bjc.6603869. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595658 Free PMC article. Clinical Trial.
Chemotherapy and quality of life in NSCLC PS 2 patients.
Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Among authors: bremnes rm. Acta Oncol. 2009;48(7):1019-25. doi: 10.1080/02841860902795240. Acta Oncol. 2009. PMID: 19274496 Clinical Trial.
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Grønberg BH, et al. Among authors: bremnes rm. J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433683 Clinical Trial.
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen Cv, Jordhøy M. Grønberg BH, et al. Among authors: bremnes rm. Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12. Eur J Cancer. 2010. PMID: 20471248 Clinical Trial.
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U. Strøm HH, et al. Among authors: bremnes rm. Clin Lung Cancer. 2015 May;16(3):183-92. doi: 10.1016/j.cllc.2014.08.005. Epub 2014 Nov 13. Clin Lung Cancer. 2015. PMID: 25481662 Free article. Clinical Trial.
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Among authors: bremnes rm. Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15. Lung Cancer. 2005. PMID: 15829326 Clinical Trial.
223 results